Press Room

AAPS 2015

Start
Sunday, October 25, 2015 - 00:00
End
Thursday, October 29, 2015 - 23:00
Location: Orlando, USA
Booth Number: 1845

HOVIONE'S PRESENTATION

Screening Methodologies for the Development of Spray-Dried Amorphous Solid Dispersions
Speaker: Marcio Temtem (Oral Drug Forms Group Leader)
Date: Tuesday, October 27, 2015
Time: 10:00 AM – 12:00 PM, OCCC - Room W310
This presentation will take place during the Roundtable Session "What a Guess! - How to Predict Which Polymer is the One for My Amorphous Solids Dispersion"

Expanding in the Right Direction
Speaker: Antonio Dinis (Director, Marketing & Communication)
Date: Tuesday, October 27 
Time: 10:25 AM - 10:40 AM, OCCC - End of 200 Aisle
Having Hovione’s expansion plans as a starting point we will explore how why capacity alone is not what make the company the leader in pharmaceutical spray drying. Development by Design cases studies will be presented to illustrate how Hovione is making strides to the third evolutionary stage of the industry.

 

Poster Session at AAPS:  

Evaporation of binary mixtures and shell formation in spray dried droplets
Pedro Valente

A Direct Approach for Spray Drying Process Development: From Laboratory to Commercial Scale
Rui Ferreira

Benchmarking the Bioperformance of Amorphous Solid Dispersions Produced by Spray Drying and a Solvent Controlled Precipitation Process
Iris Duarte

Predicting the performance of amorphous solid dispersions based on molecular descriptors and statistical analysis
Iris Duarte

Production of Co-crystals: Microfluidization vs High Shear Mixing Assisted Process
Tiago Profirio

Achieving High Efficiency Taste Masking with Particle Engineering
Inês Matos

Loss of Compactability in Roller Compaction—Influencing Parameters and Analytical Characterization
João Henriques

Analytical Qbd Model: a new stepwise methodology for analytical chemistry
Lúcia Volta e Sousa1,2, António Ramos1, Rui Loureiro1, José C. Menezes2
1 Hovione Farmaciência S.A.
2 Institute for Biotechnology and Biosciences, Instituto Superior Técnico, Universidade de Lisboa

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026